Are novel glucose‐lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta‐trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.

Importantly, our trial sequential analysis suggests that the sample size available provided inadequate statistical power to detect a significant treatment effect for CV outcomes in Black participants. CONCLUSIONS Although Black participants account for 11.7% of the diabetes population in the United States,8 participation of Black patients in clinical trials that evaluated novel glucose-lowering agents from 2013 to 2021 was less than 5% of trial enrollees. The composite endpoint of CV death/HHF was available in six trials (five trials for Black participants and six trials for White participants) (Figure 1). A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. [Extracted from the article]